- Nivolumab + ipilimumab v kombinaci s dvěma cykly chemoterapie u pacientky s karcinomem plic a pleurálním výpotkem2023 | Faculty of Medicine in Pilsen
- Report of University Hospital Hradec Králové to the clinical trial protocol No: CA209-067Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CA209-238Publication without faculty affiliation
- Výzkumná zpráva Fakultní nemocnice ke klinickému Hodnocení CA209-067Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CA209-214Publication without faculty affiliation
- Failure of adjuvant treatment for malignant melanoma - what next?2021 | Publication without faculty affiliation
- Current possibilities of immunotherapy in the treatment of malignant melanoma2018 | Faculty of Medicine in Hradec Králové
- Nivolumab in the treatment of metastatic melanoma2015 | Publication without faculty affiliation
- Immunotherapy of small cell lung cancer2020 | Publication without faculty affiliation
- Imunooncologic therapeutic options in small cell lung cancer (SCLC) therapy2020 | Faculty of Medicine in Pilsen
- Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma +12022 | Faculty of Medicine in Hradec Králové
- Editorial to Immuno-Oncotherapy News2020 | Faculty of Medicine in Pilsen
- Lung cancer on virtual ASCO 20212021 | Publication without faculty affiliation
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial2020 | Third Faculty of Medicine
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma2023 | Central Library of Charles University
- Nivolumab plus chemotherapy or ipilimumab in the first-line palliative therapy of esophageal, gastroesophageal junction, and gastric cancer2023 | Faculty of Medicine in Hradec Králové
- Generalizovaný maligní melanom léčený kombinací BRAF a MEK inhibitorů ve 3. linii terapie2023 | First Faculty of Medicine
- První zkušenosti s kombinovanou imunoterapií2021 | Publication without faculty affiliation
- Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer2018 | Faculty of Medicine in Pilsen
- CheckMate 9LA trial: commentary and clinical case report of patient with cerebellar metastasis2023 | First Faculty of Medicine
- Pleural mesothelioma2023 | Third Faculty of Medicine
- Tříleté výsledky studie CheckMate 9LA: komentář ke studii a klinická zkušenost2022 | First Faculty of Medicine